– Noted clinical investigator Dr. Ed Gane outlines program concept during 2023 AASLD presentation in Boston – Mechanism targets both integrated virus and cccDNA; expected to begin clinical testing by end of 2024 – Preclinical program data to be presented at the 2023 Hep DART Conference DURHAM, N.C. & SEATTLE – Pioneering epigenome editing company Tune Therapeutics has […]